Fig. 1.
![Fig. 1. Administration of Mpl ligand or loss of p53 protects mice from lethal myelosuppression. / Survival of p53−/− mice (knockout [KO]; n = 22) and wild-type mice (WT C57BL/6J; n = 15) that were given 50 μg/kg of PEG-rmMGDF immediately after receiving 80 mg/kg carboplatin intravenously and 7.5 Gy TBI. Control groups of the same sizes were given carrier (1% normal mouse serum in PBS) instead of PEG-rmMGDF.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/98/7/10.1182_blood.v98.7.2084/5/h81911609001.jpeg?Expires=1725237140&Signature=ceEckTL0DtyaOJg9VWaj~8FusGs2Ec8tNg0FxkB71i1DU-nPDXtb7zfYaelAFtvfZW~JcQmzARTFhJCXpZz4k-ErZ5ogbL~QMkIk~kDXEj9rmURrTGs1Lpj49peVZMMrAUDvDng7B-1UdLUImVrQ4wvqT8VK8uM~w1uDdzv5ZBVhAd6da5pSVowa2Y8SupIijwsskwWtlh4XHoaQJHtOo3gnpl8XZherzkpnyv-ZBxdVVeU2xdJneFfjgMPVhw2ER5hYYh4IiXA5AfdT~wMUy4fxicmnVG2fc4M8ExiSHJwtLYYUN8wYBcU5MavFUs4g5~gm4yzzfqNqecBxwGZU4g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Administration of Mpl ligand or loss of p53 protects mice from lethal myelosuppression.
Survival of p53−/−mice (knockout [KO]; n = 22) and wild-type mice (WT C57BL/6J; n = 15) that were given 50 μg/kg of PEG-rmMGDF immediately after receiving 80 mg/kg carboplatin intravenously and 7.5 Gy TBI. Control groups of the same sizes were given carrier (1% normal mouse serum in PBS) instead of PEG-rmMGDF.
